Drug developers' dreams of silencing RNA as a way to step in front of a range of diseases have not lived up to early-day hype ...

AstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be ...

Second, we demonstrated the broad potential utility of our ECO Synthesis platform by successfully synthesizing inclisiran, a commercially approved siRNA drug, by four different methods ranging ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts--(Newsfile ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...

"We are excited with the rapid completion of enrollment of the third safety cohort," said Robert Bitterman, CEO of Phio Pharmaceuticals. "We look forward to rapidly advancing the study to bring an ...

FORWARD-53 is an ongoing Phase 2 open-label trial of WVE-N531. Muscle biopsies are taken after 24 and 48 weeks of dosing. The ...

Final results of the OCEAN(a)-DOSE trial – published in the New England Journal of Medicine – showed that the small, interfering RNA (siRNA ... market for both drugs, if approved.

SAN FRANCISCO, CA, USA I March 13, 2025 I Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE ...